Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,258,381
  • Shares Outstanding, K 111,030
  • Annual Sales, $ 408,830 K
  • Annual Income, $ 8,010 K
  • 60-Month Beta 0.68
  • Price/Sales 12.41
  • Price/Cash Flow 88.28
  • Price/Book 7.62
Trade NEO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.04
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate 0.04
  • Prior Year 0.08
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.74 +25.49%
on 11/02/20
47.55 -0.40%
on 11/27/20
+6.11 (+14.81%)
since 10/27/20
3-Month
34.18 +38.56%
on 09/24/20
47.55 -0.40%
on 11/27/20
+9.64 (+25.56%)
since 08/27/20
52-Week
20.47 +131.36%
on 03/12/20
47.55 -0.40%
on 11/27/20
+21.56 (+83.57%)
since 11/27/19

Most Recent Stories

More News
Neo Performance Materials, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Neo Performance Materials, Inc. (NEO) (NASDAQ:NEO) will be discussing their earnings results in their call to be held on November 16, 2020 at 10:00 AM Eastern...

NEO : 47.36 (+3.61%)
NeoGenomics To Virtually Participate In Fireside Chat At The Stephens Annual Investment Conference 2020

FT. MYERS, FL / ACCESSWIRE / November 13, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

NEO : 47.36 (+3.61%)
Look for Shares of Neogenomics Inc to Potentially Pullback after Yesterday's 1.59% Rise

Neogenomics Inc (NASDAQ:NEO) traded in a range yesterday that spanned from a low of $42.85 to a high of $44.26. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of...

NEO : 47.36 (+3.61%)
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

PSCH : 155.82 (+0.57%)
OMCL : 106.57 (-0.21%)
NEO : 47.36 (+3.61%)
AMN : 66.55 (+0.17%)
XLV : 109.44 (+0.92%)
VHT : 215.00 (+1.36%)
NeoGenomics to Offer Mobile Phlebotomy Services for Liquid Biopsy Tests

National In-Home Blood Sample Collection Through ExamOne® and Metro Health Staffing, LLC

NEO : 47.36 (+3.61%)
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

PSCH : 155.82 (+0.57%)
OMCL : 106.57 (-0.21%)
NEO : 47.36 (+3.61%)
AMN : 66.55 (+0.17%)
XLV : 109.44 (+0.92%)
VHT : 215.00 (+1.36%)
% Return Seen to Date on SmarTrend Neogenomics Inc Call (NEO)

SmarTrend identified a Downtrend for Neogenomics Inc (NASDAQ:NEO) on October 6th, 2020 at $38.33. In approximately 1 month, Neogenomics Inc has returned 6.09% as of today's recent price of $40.66.

NEO : 47.36 (+3.61%)
NeoGenomics (NEO) Surpasses Q3 Earnings Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

NEO : 47.36 (+3.61%)
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million in the Third Quarter

____________________

NEO : 47.36 (+3.61%)
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEO : 47.36 (+3.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

2nd Resistance Point 48.61
1st Resistance Point 47.99
Last Price 47.36
1st Support Level 46.30
2nd Support Level 45.24

See More

52-Week High 47.55
Last Price 47.36
Fibonacci 61.8% 37.21
Fibonacci 50% 34.01
Fibonacci 38.2% 30.81
52-Week Low 20.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar